Elevated serum carboxymethyl-lysine, an advanced glycation end product, predicts severe walking disability in older women: The Women's Health and Aging Study i

Kai Sun, Richard D. Semba, Linda P. Fried, Debra A. Schaumberg, Luigi Ferrucci, Ravi Varadhan

Research output: Contribution to journalArticlepeer-review

Abstract

Advanced glycation end products (AGEs) have been implicated in the pathogenesis of sarcopenia. Our aim was to characterize the relationship between serum carboxymethyl-lysine (CML), a major circulating AGE, and incident severe walking disability (inability to walk or walking speed <0.4 m/sec) over 30 months of followup in 394 moderately to severely disabled women, <65 years, living in the community in Baltimore, Maryland (the Women's Health and Aging Study I). During followup, 154 (26.4%) women developed severe walking disability, and 23 women died. Women in the highest quartile of serum CML had increased risk of developing of severe walking disability in a multivariate Cox proportional hazards model, adjusting for age and other potential confounders. Women with elevated serum CML are at an increased risk of developing severe walking disability. AGEs are a potentially modifiable risk factor. Further work is needed to establish a causal relationship between AGEs and walking disability.

Original languageEnglish (US)
Article number586385
JournalJournal of Aging Research
Volume2012
DOIs
StatePublished - 2012

ASJC Scopus subject areas

  • Geriatrics and Gerontology

Fingerprint Dive into the research topics of 'Elevated serum carboxymethyl-lysine, an advanced glycation end product, predicts severe walking disability in older women: The Women's Health and Aging Study i'. Together they form a unique fingerprint.

Cite this